Geneva Capital Management LLC Sells 12,263 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Geneva Capital Management LLC trimmed its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 1.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 865,582 shares of the medical instruments supplier’s stock after selling 12,263 shares during the period. LeMaitre Vascular makes up approximately 1.4% of Geneva Capital Management LLC’s portfolio, making the stock its 24th biggest position. Geneva Capital Management LLC owned approximately 3.85% of LeMaitre Vascular worth $79,755,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in LMAT. Raymond James Financial Inc. bought a new stake in LeMaitre Vascular in the 4th quarter valued at about $14,900,000. DF Dent & Co. Inc. increased its position in LeMaitre Vascular by 26.2% in the 3rd quarter. DF Dent & Co. Inc. now owns 258,767 shares of the medical instruments supplier’s stock valued at $24,037,000 after buying an additional 53,797 shares in the last quarter. Barclays PLC increased its position in LeMaitre Vascular by 394.5% in the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock valued at $3,396,000 after buying an additional 29,180 shares in the last quarter. State Street Corp increased its position in LeMaitre Vascular by 3.6% in the 3rd quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier’s stock valued at $76,363,000 after buying an additional 28,525 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in LeMaitre Vascular by 4.5% in the 3rd quarter. Geode Capital Management LLC now owns 542,523 shares of the medical instruments supplier’s stock valued at $50,403,000 after buying an additional 23,443 shares in the last quarter. 84.64% of the stock is owned by institutional investors.

LeMaitre Vascular Stock Down 3.8 %

Shares of NASDAQ LMAT opened at $87.00 on Thursday. LeMaitre Vascular, Inc. has a twelve month low of $62.39 and a twelve month high of $109.58. The stock’s 50 day moving average price is $96.75 and its 200-day moving average price is $94.94. The company has a market capitalization of $1.96 billion, a PE ratio of 47.54, a PEG ratio of 2.22 and a beta of 0.96.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm had revenue of $55.81 million for the quarter, compared to the consensus estimate of $55.99 million. As a group, research analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th will be paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date of this dividend is Thursday, March 13th. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.16. LeMaitre Vascular’s payout ratio is presently 41.24%.

Analysts Set New Price Targets

A number of analysts recently commented on LMAT shares. Oppenheimer lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Barrington Research downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Wells Fargo & Company started coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They set an “equal weight” rating and a $95.00 price target for the company. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Finally, Lake Street Capital lifted their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, LeMaitre Vascular has an average rating of “Moderate Buy” and an average target price of $95.25.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.